KR20150139982A - 제약학적으로 용도되는 신규한 뉴트린 접합체 - Google Patents

제약학적으로 용도되는 신규한 뉴트린 접합체 Download PDF

Info

Publication number
KR20150139982A
KR20150139982A KR1020157034049A KR20157034049A KR20150139982A KR 20150139982 A KR20150139982 A KR 20150139982A KR 1020157034049 A KR1020157034049 A KR 1020157034049A KR 20157034049 A KR20157034049 A KR 20157034049A KR 20150139982 A KR20150139982 A KR 20150139982A
Authority
KR
South Korea
Prior art keywords
nutlin
pharmaceutical composition
neutrin
human
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157034049A
Other languages
English (en)
Korean (ko)
Inventor
마티아스 오스틴
마르쿠스 기즈
라이너 뮤즈만
프레드리히 하더
토마스 지그문트
마틴 슈나이더
Original Assignee
데벨로겐 악틴게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 데벨로겐 악틴게젤샤프트 filed Critical 데벨로겐 악틴게젤샤프트
Publication of KR20150139982A publication Critical patent/KR20150139982A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A61K47/48215—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020157034049A 2007-11-05 2008-11-05 제약학적으로 용도되는 신규한 뉴트린 접합체 Ceased KR20150139982A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07021493.7 2007-11-05
EP07021493 2007-11-05
PCT/EP2008/009320 WO2009059755A2 (en) 2007-11-05 2008-11-05 Novel neurturin conjugates for pharmaceutical use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020107012303A Division KR20100098619A (ko) 2007-11-05 2008-11-05 제약학적으로 용도되는 신규한 뉴트린 접합체

Publications (1)

Publication Number Publication Date
KR20150139982A true KR20150139982A (ko) 2015-12-14

Family

ID=40521395

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157034049A Ceased KR20150139982A (ko) 2007-11-05 2008-11-05 제약학적으로 용도되는 신규한 뉴트린 접합체
KR1020107012303A Ceased KR20100098619A (ko) 2007-11-05 2008-11-05 제약학적으로 용도되는 신규한 뉴트린 접합체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020107012303A Ceased KR20100098619A (ko) 2007-11-05 2008-11-05 제약학적으로 용도되는 신규한 뉴트린 접합체

Country Status (17)

Country Link
US (3) US9029323B2 (https=)
EP (1) EP2217282A2 (https=)
JP (2) JP2011503019A (https=)
KR (2) KR20150139982A (https=)
CN (2) CN101848735B (https=)
AU (1) AU2008324426B2 (https=)
BR (1) BRPI0819220A2 (https=)
CA (1) CA2742839A1 (https=)
CO (1) CO6280503A2 (https=)
CR (1) CR11406A (https=)
EA (1) EA201070484A1 (https=)
IL (1) IL205290A (https=)
MX (1) MX2010004899A (https=)
NZ (1) NZ585262A (https=)
SG (1) SG185946A1 (https=)
WO (1) WO2009059755A2 (https=)
ZA (1) ZA201003227B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050222070A1 (en) 2002-05-29 2005-10-06 Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung Pancreas-specific proteins
JP4838724B2 (ja) 2003-11-27 2011-12-14 デヴェロゲン アクチエンゲゼルシャフト ニュールツリンを用いる糖尿病の予防と治療方法
US8445432B2 (en) 2009-10-30 2013-05-21 Ntf Therapeutics Inc Neurturin molecules
US9127083B2 (en) 2009-10-30 2015-09-08 Ntf Therapeutics, Inc. Neurturin molecules
NZ599543A (en) * 2009-10-30 2014-02-28 Ntf Therapeutics Inc Improved neurturin molecules
US8742677B2 (en) * 2010-01-11 2014-06-03 System General Corp. LED drive circuit with a programmable input for LED lighting
CN102453725B (zh) * 2010-11-02 2014-06-11 杭州纽龙生物科技有限公司 一种重组载体、包含该重组载体的重组菌株及制备方法
JP6051378B2 (ja) 2011-05-02 2016-12-27 国立大学法人 熊本大学 幹細胞からインスリン産生細胞への分化誘導を促進する低分子化合物および該化合物を用いた幹細胞からインスリン産生細胞への分化誘導方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739307A (en) * 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US6043221A (en) * 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
CA2344277A1 (en) * 1998-09-22 2000-03-30 University Of Maryland, Baltimore Cystine knot growth factor mutants
US7442370B2 (en) * 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US20050222070A1 (en) * 2002-05-29 2005-10-06 Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung Pancreas-specific proteins
AU2003238178A1 (en) 2002-05-29 2003-12-12 Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung Pancreas-specific proteins
WO2005039643A2 (en) * 2003-10-20 2005-05-06 Nsgene A/S In vivo gene therapy of parkinson's disease
JP4838724B2 (ja) * 2003-11-27 2011-12-14 デヴェロゲン アクチエンゲゼルシャフト ニュールツリンを用いる糖尿病の予防と治療方法
EP1872790A1 (en) * 2006-06-26 2008-01-02 DeveloGen Aktiengesellschaft New formulation for increasing bioavailability of neurturin

Also Published As

Publication number Publication date
AU2008324426A1 (en) 2009-05-14
US9029323B2 (en) 2015-05-12
AU2008324426B2 (en) 2014-03-27
WO2009059755A2 (en) 2009-05-14
KR20100098619A (ko) 2010-09-08
JP2011503019A (ja) 2011-01-27
WO2009059755A3 (en) 2009-09-24
EP2217282A2 (en) 2010-08-18
CO6280503A2 (es) 2011-05-20
ZA201003227B (en) 2011-03-30
US20160060317A1 (en) 2016-03-03
JP2015057384A (ja) 2015-03-26
SG185946A1 (en) 2012-12-28
US20110003741A1 (en) 2011-01-06
CN101848735A (zh) 2010-09-29
BRPI0819220A2 (pt) 2019-02-26
CN101848735B (zh) 2014-07-23
IL205290A (en) 2014-01-30
IL205290A0 (en) 2010-12-30
CR11406A (es) 2010-10-25
US20130231283A1 (en) 2013-09-05
CN104288775A (zh) 2015-01-21
CA2742839A1 (en) 2009-05-14
EA201070484A1 (ru) 2011-04-29
NZ585262A (en) 2012-06-29
MX2010004899A (es) 2010-09-07

Similar Documents

Publication Publication Date Title
KR101011081B1 (ko) Ｐｅｇ화된 ｇｌｐ-1 화합물
US20160060317A1 (en) Novel neurturin conjugates for pharmaceutical use
IL115965A (en) Polyethylene derivatives of BDNF and 3 NT
CN101870728A (zh) 新型Exendin变体及其缀合物
AU2007207268A1 (en) Medicament for treatment of tumor and the use thereof
JP2017205120A (ja) コリンエステラーゼ部分とポリマーとのコンジュゲート
EP3539570B1 (en) Pegylated endostatin analogue and application thereof
AU2017246404A1 (en) Conjugated C1 esterase inhibitor and uses thereof
KR20180108510A (ko) 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
KR101104574B1 (ko) 폴리에틸렌글리콜로 화학적으로 수식된 인간 성장 호르몬, 이의 제조방법 및 용도
WO2014184564A1 (en) Novel polymer conjugates
CN101596320B (zh) 一种治疗肿瘤的药物及其应用
KR20040066712A (ko) 인간 성장 호르몬의 결합체

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20151130

Application number text: 1020107012303

Filing date: 20100604

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20151230

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160111

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160810

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160111

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I